Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1

Masakazu Toi, Frances Boyle, Young-Hyuck Im, Mattea Reinisch, David Molthrop, Zefei Jiang, Ran Wei, Francisco Sapunar, Brenda R Grimes, Sarah Cassidy Nabinger, Stephen R D Johnston, Masakazu Toi, Frances Boyle, Young-Hyuck Im, Mattea Reinisch, David Molthrop, Zefei Jiang, Ran Wei, Francisco Sapunar, Brenda R Grimes, Sarah Cassidy Nabinger, Stephen R D Johnston

Abstract

The monarchE Cohort 1 patient population was enrolled based on high-risk clinicopathological features that can easily be identified as part of routine clinical breast cancer evaluation. Efficacy data from Cohort 1 demonstrate substantial evidence of benefit for adjuvant abemaciclib+ET in patients with HR+, HER2- early breast cancer at high risk of recurrence (ClinicalTrials.gov: NCT03155997 [monarchE]).

Keywords: CDK4/6; Ki-67; abemaciclib; adjuvant; early breast cancer.

© The Author(s) 2022. Published by Oxford University Press.

Figures

Figure 1.
Figure 1.
Invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in the Cohort 1 subpopulation at additional follow-up 1 (AFU1). (a) Kaplan-Meier curve of IDFS in Cohort 1. (b) Kaplan-Meier curve of DRFS in Cohort 1. A zoomed in version is provided within each Kaplan-Meier curve to allow better visualization of curve separation.

References

    1. Johnston SRD, Harbeck N, Hegg R, et al. . Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987-3998. 10.1200/JCO.20.02514.
    1. Harbeck N, Rastogi P, Martin M, et al. . Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2021;32(12):1571-1581.
    1. VERZENIO™ (abemaciclib) Pharmaceuticals and Medical Devices Agency FY (April 2021-March 2022). 2021. Japan: Pharmaceuticals and Medical Devices Agency (PMDA).
    1. VERZENIOS™ (abemaciclib) European Medicines Agency. 2022. Amsterdam, Netherlands: European Medicines Agency.
    1. Rugo HS, O’Shaughnessy J, Boyle F, et al. . Adjuvant abemaciclib combined with endocrine therapy for high risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022;33(6):616-627.
    1. Forbes JF, Cuzick J, Buzdar A, et al. ; Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Arimidex, Tamoxifen Alone or in Combination (ATAC) Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45-53. 10.1016/S1470-2045(07)70385-6.
    1. Group EBCTC. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341-1352.
    1. Sheffield KM, Peachey JR, Method M, et al. . A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. Future Oncol. 2022;18(21):2667-2682. 10.2217/fon-2022-0310.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren